Listen to leading experts provide an update on the underlying pathobiology of esophageal squamous cell carcinoma, and review current and emerging therapies.
- Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan
This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an independent medical education grant from Novartis. This activity is provided by touchIME.
For further information visit our website: https://touchoncologyime.org/targeting-pathobio-of-ESCC-and-emerging-impact-of-IO